PMC3794845_01
The patient's clinical course before administration of paclitaxel and bevacizumab.. Notes: The line graph shows changes in tumor markers and serum Her2 (human epidermal growth factor receptor type 2) and indicates the individual treatments (A). Macroscopic and computed tomography findings of the primary tumor/multiple liver metastases (B). *represents the childbirth delivery day.. Abbreviations: Ca15-3, cancer antigen 15-3; CAF, cyclophosphamide, adriamycin, and 5-fluorouracil therapy; CEA, carcinoembryonic antigen; E, eribulin; TCH, docetaxel, carboplatin, and trastuzumab; tras, trastuzumab; Vino, vinorelbine.
ott-6-1393Fig1.jpg
PMC3794845_01_ott-6-1393Fig1.jpg
f1-ott-6-1393
Tokyo, Japan) (60 mg/m2), and fluorouracil (500 mg/m2) therapy (Figure 1).
The patient's clinical course after administration of paclitaxel and bevacizumab combination therapy.. Notes: (A and B) show the findings of the primary tumor in the first and second course of the treatment, respectively. The inverted triangles ( ) indicate the massive hemorrhage.. Abbreviations: B, bevacizumab; p, paclitaxel.
ott-6-1393Fig2.jpg
PMC3794845_01_ott-6-1393Fig2.jpg
f2-ott-6-1393
As it was considered that the primary tumor became resistant to anti-HER2-based therapy, combination therapy with paclitaxel (90 mg/m2 on days 1, 8, and 15) and bevacizumab (10 mg/m2 on days 1 and 15) was initiated as a seventh-line therapy after removal of the pleural effusion by thoracocentesis (Figure 2).